Rani Therapeutics Files 8-K on Officer/Director Changes
Ticker: RANI · Form: 8-K · Filed: Apr 30, 2025 · CIK: 1856725
| Field | Detail |
|---|---|
| Company | Rani Therapeutics Holdings, Inc. (RANI) |
| Form Type | 8-K |
| Filed Date | Apr 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, officer-appointment, director-election, compensation
Related Tickers: RANI
TL;DR
Rani Therapeutics (RANI) filed an 8-K detailing leadership changes and executive compensation updates.
AI Summary
Rani Therapeutics Holdings, Inc. filed an 8-K on April 30, 2025, reporting events as of April 24, 2025. The filing indicates changes related to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors or officers can indicate internal shifts or strategic realignments that may carry inherent business risks.
Key Players & Entities
- Rani Therapeutics Holdings, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 2051 Ringwood Avenue, San Jose, California 95131 (address) — Principal executive offices
- (408) 457-3700 (phone_number) — Registrant's Telephone Number
FAQ
What specific changes were made regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as compensatory arrangements for certain officers, but the specific details of these changes are not provided in the summary text.
When were the events reported in this 8-K dated?
The date of the earliest event reported is April 24, 2025.
What is the exact name of the company filing this report?
The exact name of the registrant is Rani Therapeutics Holdings, Inc.
In which state was Rani Therapeutics Holdings, Inc. incorporated?
Rani Therapeutics Holdings, Inc. was incorporated in Delaware.
What is the company's principal executive office address?
The address of the principal executive offices is 2051 Ringwood Avenue, San Jose, California 95131.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 30, 2025 regarding Rani Therapeutics Holdings, Inc. (RANI).